Biophytis SA · EURONEXT:ALBPS
Biophytis SA — Investor Presentation (January 2024)
25 slides from Biophytis SA's investor presentation, January 2024

Slide 1: January 2024 | Euronext: ALBPS – Nasdaq: BPTS
January 2024 I Euronext: ALBPS – Nasdaq: BPTS

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential

Slide 3: Today's Corporate Highlights
Today’s Corporate Highlights Biophytis SA • Is a clinical-stage biotechnology company specialized in the development HQ location: Paris, France of therapeutics that are aimed at slowing the degenerative processes associated with aging • Our small molecules are aimed at stimulating biological resilie

Slide 4: Executive Team
Executive Team Stanislas Veillet – Founder & CEO • PhD in genetics, AgroParisTech • 25+ years in biotech; Pharmacia-Monsanto, Danone Group Nicolas Fellmann – CFO Edouard Bieth – CBO • Over 25 years' experience in finance (Onxeo, BioAlliance Pharma, • Over 18 years' experience in the pharmaceutical i

Slide 5: Our Clinical Pipeline as of today
Our Clinical Pipeline as of today Candidate Indication Program Preclinical Phase 1 Phase 2 Phase 3 Regulatory Market Covid-19 COVA Sarcopenia Duchenne Muscular Dystrophy Dry AMD Macuneos (BIO201) Stargardt XXX : orphan diseases 5

Slide 6: Ruvembri: Mechanism of Action
Ruvembri: Mechanism of Action Ruvembri triggers two important MAS receptor downstream signaling-pathways in myocytes: • PI3K/AKT/mTOR: Increases protein synthesis MAS • AMPK/ACC: Stimulates Receptor energy production MAS activation in skeletal and smooth muscles stimulates muscle metabolism and stre

Slide 7: Ruvembri stimulates respiratory function by activating the MAS receptor
Ruvembri stimulates respiratory function by activating the MAS receptor, a key component in the renin-angiotensin system, the target of SARS-CoV2 • Ruvembri activates the MAS receptor, a key component of the SARS-CoV2 protective arm of the Renin- Renin (Covid-19) Angiotensin System (RAS), involved i

Slide 8: in COVID-19
in COVID-19 8

Slide 9: COVA Study: Targeting Hospitalized Patients with severe COVID-19
COVA Study: Targeting COVID-19 Hospitalized Patients with severe COVID-19 Patients aged 45 and above, with proven COVID-19, Severe cases: Severe cases:signs of respiratory de-compensation, and severe respiratory symptoms: not requiring with hospitalized ventilation hypoxemia, tachypnea or pneumonia

Slide 10: International Phase 2-3 COVA clinical trial of Ruvembri
International Phase 2-3 COVA clinical trial to evaluate the safety and efficacy of Ruvembri in the treatment of severe forms of COVID-19 Design Endpoints & Study Follow-Up Patient Population • Administration of • Age: 45 years old or over 350 mg b.i.d of Ruvembri • Primary endpoint: proportion of •

Slide 11: Positive results in severe COVID-19: respiratory failure or early death
Positive results strongly supporting therapeutic potential of Ruvembri in severe COVID-19: respiratory failure or early death RESPIRATORY FAILURE OR EARLY DEATH : THE STUDY MET PRIMARY ENDPOINT • Reduction in the risk of early death or respiratory failure at day 28 by 44% (p=0.043, CMH test) • Time

Slide 12: Positive results in severe COVID-19: mortality and safety
Positive results strongly supporting therapeutic potential of Ruvembri in severe COVID-19: mortality and safety MORTALITY FOLLOW-UP OVER 90 DAYS AND SAFETY • Kaplan Meier post hoc analysis showed a reduction in the risk of death at day 90 of 43% (p=0.076) in the ITT population and 70% (p=0.016) in t

Slide 13: Biophytis initiates market access processes for Ruvembri
Biophytis initiates market access processes for Ruvembri treatment of severe forms of COVID-19 Early access • EAP in France: application for early access will be re-submitted as soon as possible • EAP in Brazil: EAP program authorized by ANVISA with initiation of program expected in Q1 2024 and firs

Slide 14: in Sarcopenia
in Sarcopenia 14

Slide 15: SARA project: Treatment for Sarcopenia, a large unmet medical need
SARA project: Treatment for Sarcopenia, a large unmet medical need NO CURRENTLY APPROVED DRUGS • Age-related degeneration of skeletal muscle characterized by a loss of muscle mass, strength and functional issues such as the ability to stand and/or walk • A major cause of mobility disability, resulti

Slide 16: SARA-INT: Phase 2 trial overview
SARA-INT: Phase 2 trial overview Design Endpoints Patient Population • Global, double-blind, randomized, Primary • Age: 65 years old or over placebo-controlled trial: • 400-meter walk test (400MWT) - • Low mobility measured by Short NCT03452488 0.05 m/s is considered the minimal Performance Physical

Slide 17: Positive results obtained in SARA-INT phase 2 trial
Positive results obtained in SARA-INT phase 2 trial Ruvembri significantly improves the gait speed in the 400 MWT, the primary endpoint of SARA-INT Phase 2 trial, in the PP population after 6 months of treatment • Global, double-blind, randomized, placebo-controlled trial in patients Change from bas

Slide 18: SARA-31 – Phase 3 development plan
SARA-31 – Phase 3 development plan Design Endpoints Patient Population • Global, double-blind, randomized, Primary • Age: 65 years old or over phase 3 placebo-controlled trial • Major Mobility Disability (MMD) • Low mobility measured by Short • Assess safety and efficacy assessed by the inability to

Slide 19: in DMD
in DMD 19

Slide 20: Treatment Overview for Duchenne Muscular Dystrophy (DMD)
Treatment Overview for Duchenne Muscular Dystrophy (DMD) Proportion of ambulatory class in DMD1 Rare, genetic neuromuscular disease in male children characterized by accelerated degeneration of muscles, responsible for loss of mobility, respiratory failure and 100% cardiomyopathy, leading to prematu

Slide 21: Preparing to start phase 1-2 clinical study in DMD
Preparing to start phase 1-2 clinical study in DMD Design Endpoints Patient Population • Age: ≥12 years old • A Randomized, Double-Blind, multi-center • Primary: change from baseline on Peak • Non-ambulatory DMD patients Phases 1-2 Study Expiratory Flow (PEF) • Secondary: The Forced Vital Capacity (

Slide 22: Key milestones in the development of Ruvembri
Key milestones in the development of Ruvembri Achieved in the last 12 months Anticipated in the next 12 months • Launch of Early Access programs in France and Brazil • Phase 2/3 COVA Study : Results published and promising COVA clinical benefits for Ruvembri • Application for conditional marketing a

Slide 23: Scientific Advisory Board
Scientific Advisory Board Pr. Jean Mariani Dr. Roger Fielding • Professor of neuroscience and biology of aging and • Professor of Medicine, Tufts University School of Medicine Director of Charles Foix Institute of Longevity at • Director and Sr. Scientist Jean Mayer USDA Human Sorbonne University Nu

Slide 24: Key financial figures
Financial data Shareholding structure Listing Euronext (ALBPS) and Nasdaq (BPTS) Key Cash position: financial § €5.8m (June 30, 2023) figures § €5.4m raised and €2m in convertible bonds drawn down since June 2023 Analyst • H.C. Wainwright – Joe Pantginis, Ph.D. • Kepler Cheuvreux – Nicolas Pauillac

Slide 25: THANK YOU
THANK YOU Contacts: Stanislas Veillet – CEO stanislas.veillet@biophytis.com Nicolas Fellmann – CFO nicolas.fellmann@biophytis.com Edouard Bieth – CBO edouard.bieth@biophytis.com Investor relations: investors@biophytis.com www.biophytis.com
Source: Internet Archive copy of biophytis.com
More decks from Biophytis SA
Investor Presentation (August 2026)19 slides · August 2026
Investor Presentation (August 2026)19 slides · August 2026
Investor Presentation (March 2026)21 slides · March 2026
Investor Presentation (March 2026)21 slides · March 2026
Investor Presentation (January 2025)32 slides · January 2025
Investor Presentation (December 2024)48 slides · Dec 6, 2024